Literature DB >> 9315494

Trazodone, a double blind trial for treatment of erectile dysfunction.

W Meinhardt1, P I Schmitz, R F Kropman, R B de la Fuente, A A Lycklama à Nijeholt, J Zwartendijk.   

Abstract

OBJECTIVE: to assess the effectiveness of oral trazodone 150 mg/d for treatment of erectile dysfunction. PATIENTS AND METHODS: A double-blind, placebo controlled, multicentre trial. A run-in period of two weeks was followed by four weeks of medication. Evaluation was done by patients diary, a questionnaire and Rigiscan nightly penile tumescence and rigidity (NPTR) measurements in the second and sixth week of the trial.
RESULTS: 69 patients were randomised, two patients never returned for follow-up, nine patients stopped the medication due to side-effects, so 58 patients are evaluable for effect assessment. Half of the patients suffered psychogenic impotence. There was no significant difference in the subjective results of trazodone compared to placebo. Side effects occurred more often with the use of trazodone, but this was not statistically significant.
CONCLUSION: In a group of patients, that was not selected on the basis of the etiology of the erectile dysfunction, nor selected on the duration of the complaint, the efficacy of trazodone 150 mg/d, could not be shown.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9315494     DOI: 10.1038/sj.ijir.3900272

Source DB:  PubMed          Journal:  Int J Impot Res        ISSN: 0955-9930            Impact factor:   2.896


  8 in total

1.  Erectile dysfunction: diagnosis and management with newer oral agents.

Authors:  C C Carson
Journal:  Proc (Bayl Univ Med Cent)       Date:  2000-10

Review 2.  Comparative tolerability and efficacy of treatments for impotence.

Authors:  W Meinhardt; R F Kropman; P Vermeij
Journal:  Drug Saf       Date:  1999-02       Impact factor: 5.606

3.  The efficacy of sildenafil in different etiologies of erectile dysfunction.

Authors:  M Başar; U Y Tekdogan; E Yilmaz; H Başar; A Atan; E Batislam
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

Review 4.  Central nervous system-acting agents and the treatment of erectile and sexual dysfunction.

Authors:  Culley C Carson
Journal:  Curr Urol Rep       Date:  2007-11       Impact factor: 3.092

5.  Extended-release Trazodone in Major Depressive Disorder: A Randomized, Double-blind, Placebo-controlled Study.

Authors:  David V Sheehan; Harry A Croft; E Roderich Gossen; Randy J Levitt; Claire Brullé; Sylvie Bouchard; Anna Rozova
Journal:  Psychiatry (Edgmont)       Date:  2009-05

Review 6.  Central nervous system agents in the treatment of erectile dysfunction: how do they work?

Authors:  J Allard; F Giuliano
Journal:  Curr Urol Rep       Date:  2001-12       Impact factor: 2.862

Review 7.  A risk-benefit assessment of sildenafil in the treatment of erectile dysfunction.

Authors:  D Vitezic
Journal:  Drug Saf       Date:  2001       Impact factor: 5.228

Review 8.  Targeting the Unfolded Protein Response as a Disease-Modifying Pathway in Dementia.

Authors:  Emad Sidhom; John T O'Brien; Adrian J Butcher; Heather L Smith; Giovanna R Mallucci; Benjamin R Underwood
Journal:  Int J Mol Sci       Date:  2022-02-11       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.